US Pharma MarketingYarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial
Yarrow Bioscience raises $150M; AbbVie Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and…
Plus news about Sino Biopharm and AtomVie.
Yarrow gets more money: New Haven-based Yarrow Bioscience priced a $150 million offering at $26 per share {$YARW}, about $2.50 below its Thursday closing ...
Source: Endpoints News